Genetic Signatures Reports $5.4M Quarterly Sales, Up 20% QoQ
Genetic Signatures Ltd reports a robust start to FY2026 with a 20% quarterly sales increase, driven by new US contracts and strong growth in EMEA and Australia. The company also bolsters its leadership with a new CTO appointment.
- Q1 FY2026 sales rise 20% to $5.4 million
- First commercial US order and two new US contracts signed
- EMEA gastrointestinal testing revenue up 52%
- Appointment of Dr Susanne Pedersen as Chief Technology Officer
- Strong cash position of $28.2 million supports growth and R&D
Strong Quarterly Sales Momentum
Genetic Signatures Ltd has kicked off FY2026 with its highest quarterly revenue since the COVID-19 pandemic, reporting $5.4 million in sales for Q1. This marks a 20% increase over the previous quarter and a 15% rise compared to the same period last year. The growth reflects broad-based commercial success across Australia, EMEA, and the US.
US Market Expansion Gains Traction
The US market, a key focus for the company’s global expansion, saw its first commercial order in the quarter. Genetic Signatures secured two new contracts with integrated healthcare organisations, including a major nonprofit system serving 56 hospitals. The initial shipment of test kits was delivered in September, with testing expected to commence early in Q2 FY2026. A third contract was signed shortly after quarter-end, signaling growing momentum in this strategic market.
EMEA and Australia Drive Continued Growth
In the EMEA region, revenue increased by 26.6% year-on-year, led by a remarkable 52% jump in gastrointestinal testing. The company’s EasyScreen™ Gastrointestinal Parasite Detection Kit is gaining traction, supported by ongoing engagements with UK National Health Service trusts. Meanwhile, Australia benefited from new business with existing customers and seasonal respiratory testing demand during the southern hemisphere winter.
Innovation and Leadership Strengthen Future Prospects
Genetic Signatures is advancing its automated, high-throughput testing platform through collaborations with Tecan Group and Repado, focusing on integrating software and instrumentation to optimise laboratory workflows. The appointment of Dr Susanne Pedersen as Chief Technology Officer adds significant expertise in molecular diagnostics development and commercialisation, positioning the company to accelerate product innovation and market penetration.
Financial Position Supports Strategic Growth
The company ended the quarter with a robust cash and term deposit balance of $28.2 million, providing a solid foundation for continued investment in commercial initiatives and research and development. Despite a net operating cash outflow of $2.1 million, the strong cash reserves underpin confidence in sustaining growth and expanding the global footprint.
Bottom Line?
With solid sales growth and strategic US contracts, Genetic Signatures is poised for a pivotal year ahead.
Questions in the middle?
- How quickly will US commercial testing ramp up following initial shipments?
- What impact will Dr Pedersen’s leadership have on accelerating product innovation?
- Can EMEA partnerships translate into sustained revenue growth beyond gastrointestinal testing?
